Skip to content

Drug interactions

Bosutinib + Eslicarbazepine

Severity: Major

Bosutinib and Eslicarbazepine: major interaction.

Last updated

For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.

Summary

Bosutinib is a CYP3A4 and P-gp substrate, and strong inducers reduce its exposure dramatically. Eslicarbazepine is weaker, but a meaningful decrease could cause loss of leukemia control.

What this interaction means in plain words

Bosutinib and Eslicarbazepine can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.

Bosutinib belongs to Oncology; Eslicarbazepine belongs to Central Nervous System.

Evidence level: Moderate

Why it happens

Eslicarbazepine induces CYP3A4 and possibly P-glycoprotein, reducing bosutinib exposure.

What to do

Avoid the combination and use a non-inducing anticonvulsant; if unavoidable, monitor molecular response.

What to ask your pharmacist

  • Does the benefit of taking both outweigh the risk in my case?
  • Do I need any blood test, ECG or other check while on both?
  • What early warning signs should I watch for, and what should I do if they appear?

Bring a full list of your medicines, including over-the-counter products, supplements and herbal remedies, to every pharmacy visit.

Pro+ members

Unlock the full page

Create an account and start a Pro+ trial to unlock the full management advice for Bosutinib and Eslicarbazepine, the additional notes, the evidence detail and the whole-prescription interaction checker.

  • Full clinical management advice
  • Additional notes
  • Evidence detail
  • Interaction checker for a whole prescription

Try Pro+ free for 14 days on the web. No card needed.

Frequently asked questions

Can I take Bosutinib with Eslicarbazepine?

MediHelp rates the interaction as major. Bosutinib and Eslicarbazepine can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Bosutinib is a CYP3A4 and P-gp substrate, and strong inducers reduce its exposure dramatically. Eslicarbazepine is weaker, but a meaningful decrease could cause loss of leukemia control.

How serious is the interaction between Bosutinib and Eslicarbazepine?

MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid the combination and use a non-inducing anticonvulsant; if unavoidable, monitor molecular response.

What other medicines interact with Eslicarbazepine?

MediHelp also lists interactions of Eslicarbazepine with, for example, Mavacamten, Rilpivirine, Artemether / lumefantrine. The full list is on the Eslicarbazepine page.

Full monographs, dosing and an interaction checker in the MediHelp app

Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.

Browse A–Z · Drug interactions

Get the app Sign in